BioSpace News Archive

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has signed memorandums of understanding with Samyang Holdings to advance development of a messenger ribonucleic acid (mRNA) vaccine for COVID-19 and with GC Pharma to develop mRNA vaccines and therapeutics for respiratory infections and other diseases more broadly.

Calithera Biosciences, Inc. (Nasdaq: CALA), today shared final results from the Phase 2 CANTATA study evaluating the company’s glutaminase inhibitor telaglenastat (CB-839).

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD® technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2021 and produced a recent business update.

Stericycle, Inc., a leading provider of medical waste management, secure information destruction and patient engagement solutions, announced chief executive officer Cindy J. Miller has been named to the Forbes 50 Over 50 list.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute.

MEI Pharma, Inc. (NASDAQ: MEIP), and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib,

Incisive Genetics Inc. (“IG”), a biotech company specializing in the research and development of a novel non-viral delivery platform for targeted CRISPR-based gene therapies, announced today the appointment of Kevin Chow, Ph.D. as President.

entrinsic bioscience (EBS) announced that it has secured $49 million in non-dilutive growth capital from Jefferies Group LLC’s subsidiary, Jefferies Funding LLC (Jefferies)

Crestone, Inc. today announced the first patient has been enrolled in a Phase 2 clinical trial of CRS3123 for the treatment of Clostridioides difficile infection (CDI).